Has Johnson & Johnson (JNJ) Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing’s for sure: You’ll never discover truly great investments unless you actively look for them. Let’s discuss the ideal qualities of a perfect stock, and then decide whether Johnson & Johnson (NYSE:JNJ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it’s certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can’t produce profits from them. Strong margins ensure that the company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management’s attention. Companies with strong balance sheets don’t have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can’t afford to pay too much for even the best companies. By using normalized figures, you can see how a stock’s simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can’t be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let’s take a closer look at Johnson & Johnson.

Factor What We Want to See Actual Pass or Fail?
Growth 5-year annual revenue growth > 15% 1.9% Fail
1-year revenue growth > 12% 3.4% Fail
Margins Gross margin > 35% 67.8% Pass
Net margin > 15% 16.1% Pass
Balance sheet Debt to equity < 50% 26.4% Pass
Current ratio > 1.3 1.87 Pass
Opportunities Return on equity > 15% 17.4% Pass
Valuation Normalized P/E < 20 22.37 Fail
Dividends Current yield > 2% 3.2% Pass
5-year dividend growth > 10% 8.4% Fail
Total score 6 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Johnson & Johnson last year, the company gained back one of the three points it lost from 2011 to 2012. Rising margins brought on the improvement, and the shares have responded well, climbing almost 20% over the past year.

Most investors think of Johnson & Johnson’s consumer products as the leading edge of its massive health-care business. But what elevated J&J into the ranks of the Dow Jones Industrials is its diverse set of larger segments, which include both pharmaceutical development and medical-device manufacturing.

In fact, J&J’s pharmaceutical business is well-poised to challenge other industry leaders. With the company having relatively little exposure to patent-cliff issues, J&J is taking aim at rivals’ blockbuster drugs. For instance, its Invokana drug to treat Type 2 diabetes proved itself against Merck & Co., Inc. (NYSE:MRK)‘s Januvia, giving it the inside track to become the first FDA-approved SGLT2 inhibitor. Meanwhile, sales of J&J’s anti-inflammatory Stelara hit $1 billion in 2012, and with the drug showing significant improvement compared to Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE)‘s Enbrel, it has even more potential to grow.

The big question facing J&J, though, is whether it should follow the trend of other major pharmaceutical companies and break itself into its component parts. For the most part, CEO Alex Gorsky seems to like the company’s conglomerate nature, although he may be open to minor strategic moves such as selling off its diagnostics business.

For J&J to improve, it needs to get its earnings growing a bit faster and produce a little more dividend growth. Blockbuster drugs might be just the ticket to the success J&J needs to get closer to perfection.

The article Has Johnson & Johnson Become the Perfect Stock? originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!